This is the authors' abstract. We don't add key points for this paper.
Objectives: This study aimed to identify specific microbiota associated with diarrhea-predominant irritable bowel syndrome (IBS-D) and to evaluate clinical improvement in IBS-D according to changes in gut microbiota abundance following treatment with Hangeshashinto (HST), an anti-inflammatory Kampo medicine.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
吉田 et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: